These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38447274)

  • 41. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
    Keary IP; Ravasio R; Fullarton JR; Manzoni P; Lanari M; Paes BA; Carbonell-Estrany X; Baraldi E; Tarride JÉ; Rodgers-Gray B
    PLoS One; 2023; 18(8):e0289828. PubMed ID: 37561741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An outbreak of RSV infections in a neonatology clinic during the RSV-season.
    Vakrilova L; Nikolova SH; Slavov S; Radulova P; Slancheva B
    BMC Pediatr; 2021 Dec; 21(1):567. PubMed ID: 34895173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis.
    Halfhide CP; Brearey SP; Flanagan BF; Hunt JA; Howarth D; Cummerson J; Edwards S; Hart CA; Smyth RL
    Thorax; 2009 Sep; 64(9):798-805. PubMed ID: 19497921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus.
    Larrañaga CL; Ampuero SL; Luchsinger VF; Carrión FA; Aguilar NV; Morales PR; Palomino MA; Tapia LF; Avendaño LF
    Pediatr Infect Dis J; 2009 Oct; 28(10):867-73. PubMed ID: 19738511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic manifestations of respiratory syncytial virus infection in premature infants.
    Greenough A; Broughton S
    Pediatr Infect Dis J; 2005 Nov; 24(11 Suppl):S184-7, discussion S187-8. PubMed ID: 16378044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
    Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR; Fergie J; Goldstein M; Brannman L
    Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour.
    Resch B; Resch E; Müller W
    Paediatr Respir Rev; 2013 Jun; 14(2):130-6. PubMed ID: 23375547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab.
    Manzoni P; Baraldi E; Luna MS; Tzialla C
    Am J Perinatol; 2022 Dec; 39(S 01):S7-S13. PubMed ID: 36307092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetics of Respiratory Syncytial Virus (RSV) Memphis Strain 37 (M37) Infection in the Respiratory Tract of Newborn Lambs as an RSV Infection Model for Human Infants.
    Larios Mora A; Detalle L; Van Geelen A; Davis MS; Stohr T; Gallup JM; Ackermann MR
    PLoS One; 2015; 10(12):e0143580. PubMed ID: 26641081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.
    Dieussaert I; Hyung Kim J; Luik S; Seidl C; Pu W; Stegmann JU; Swamy GK; Webster P; Dormitzer PR
    N Engl J Med; 2024 Mar; 390(11):1009-1021. PubMed ID: 38477988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Survey of Parental Knowledge of Respiratory Syncytial Virus and Other Respiratory Infections in Preterm Infants.
    Bracht M; Bacchini F; Paes B
    Neonatal Netw; 2021 Jan; 40(1):14-24. PubMed ID: 33479007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
    Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
    J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence of respiratory syncytial virus bronchiolitis in hospitalized infants born at 33-36 weeks of gestational age compared with those born at term: a retrospective cohort study.
    Greenberg D; Dagan R; Shany E; Ben-Shimol S; Givon-Lavi N
    Clin Microbiol Infect; 2020 Feb; 26(2):256.e1-256.e5. PubMed ID: 31181285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER; Winer IH; Oladapo A; Wojdyla M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
    Winterstein AG; Knox CA; Kubilis P; Hampp C
    JAMA Pediatr; 2013 Dec; 167(12):1118-24. PubMed ID: 24126903
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics.
    Krilov LR; Anderson EJ
    J Perinatol; 2020 Aug; 40(8):1135-1144. PubMed ID: 32499597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.